Sirolimus use and cancer incidence in US kidney transplant recipients
Recently we added to the Library as well as a blog a very good individual patient meta-analysis of the use of sirolimus showing that it was associated with a reduction in cancer incidence but also with an increased rate of death after kidney transplantation. Now we have a study of data from the US transplant registry […]
Read moreOctober 2012 Transplant Trial Watch now online
The October edition of the Transplant Trial Watch is now available on the CET website. Each month, our team summarise and assess the quality of 10 important randomised controlled trials in the field of solid organ transplantation. This month, trials include sirolimus in the prevention of skin cancer in transplant recipients, machine perfusion in extended […]
Read moreSirolimus and secondary skin cancer prevention in kidney transplantation
Sylvie Euvrard and her colleagues (New England Journal of Medicine 2012; 367:329) have performed a multicentre randomised trial in patients on a calcineurin inhibitor who had developed at least 1 squamous cell cancer of the skin after renal transplantation. Patients were randomised to either continue on the calcineurin inhibitor or to be converted to sirolimus. […]
Read more